{"id":"W2163450464","doi":"10.1200/jco.2014.59.2139","title":"Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BC Cancer Agency; Weill Cornell Medical College; Houston Methodist Research Institute; Università di Bologna; Queen's University; National Cancer Institute; University of Rochester; University of Toronto; Memorial Sloan-Kettering Cancer Center; F. Hoffmann-La Roche; Sveučilište u Zagrebu; Pharmacyclics; Genentech; Università degli Studi del Piemonte Orientale; Celgene","keywords":"Obinutuzumab; Medicine; Rituximab; CD20; Lymphoma; Internal medicine; Oncology; Nuclear medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002058195,0.001095782,0.002125004,0.000263343,0.0002487338,0.0008735021,0.0007181677,0.001083832,0.004024198],"category_scores_gemma":[0.001717402,0.0004254569,0.001743679,0.0002403175,0.0008772663,0.000551381,0.0003804084,0.001634333,0.0006415261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008315321,"about_ca_system_score_gemma":0.001193895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009506915,"about_ca_topic_score_gemma":0.002453004,"domain_scores_codex":[0.9993004,0.0004799471,0.00003026916,0.00008163832,0.00003707654,0.0000707516],"domain_scores_gemma":[0.998857,0.0003888249,0.0002626199,0.00009875833,0.0000603282,0.0003323095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9835899,0.00242894,0.001676613,0.0002167587,0.00111939,0.00003828526,0.00003973508,0.000356656,0.001622246,0.00006936224,0.0004878763,0.008354157],"study_design_scores_gemma":[0.9567052,0.03951025,0.002220632,0.0000154767,0.0005083384,0.00002692767,0.00001357313,0.0002888561,0.0002145092,0.00006441938,0.000425057,0.00000684125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926713,0.002746159,0.0003572714,0.000436279,0.0001829387,0.001944178,0.0006719392,0.00006117214,0.0009287836],"genre_scores_gemma":[0.9908769,0.001441594,0.001243721,0.0009272321,0.0002089745,0.002025931,0.001578777,0.0000182394,0.001678611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004024198,"threshold_uncertainty_score":0.01346231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1019630916029561,"score_gpt":0.4113322242863002,"score_spread":0.309369132683344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}